Oncology Learning NetworkMAJIC-PV Study Indicates Ruxolitinib Treatment Yields Superior Responses for Patients with Polycythemia Vera

Polycythemia vera often leads to thrombosis, hemorrhage, transformation to myelofibrosis, and early death.

A new study titled “MAJIC-PV”, led by Dr. Claire Harrison, reveals that the drug ruxolitinib could offer superior outcomes in patients suffering from polycythemia vera (PV), a rare form of blood cancer. This research brings to light the potential of ruxolitinib in extending event-free survival, overall survival, and molecular response among patients intolerant to hydroxycarbamide, a standard treatment for PV.

Key Points:

• The phase 2 MAJIC-PV trial results demonstrate that ruxolitinib outperforms the best available therapy in patients intolerant to hydroxycarbamide suffering from polycythemia vera (PV).
• Ruxolitinib treatment showed enhanced event-free survival, complete response, molecular response, and overall durable responses.
• The study suggests that molecular response (the reduction of JAK2 variant allele frequency by 50%) is tied to event-free survival, progression-free survival, and overall survival.

Additional Points:

• Patients treated with ruxolitinib had superior thrombosis-free survival and time to discontinuation of treatment.
• Controlling all parameters of the blood count, regardless of the therapy, was associated with event-free survival.
• Additional driver mutations, particularly SXR1 mutations, correlated with worse event-free survival and decreased likelihood of achieving a molecular response.
• No new safety concerns were associated with ruxolitinib, a fact important for practitioners considering the treatment for their patients.

Conclusion:

• The MAJIC-PV study affirms the effectiveness of ruxolitinib in managing PV, particularly for hydroxycarbamide-intolerant patients, with improved event-free and overall survival rates. The findings also underscore the importance of controlling blood count parameters and monitoring the JAK2 variant allele frequency as novel methods of managing disease progression.

Hematology/Oncology Latest Posts

• Cancer Care Quality Declined After Hospital’s Acquisition, Study FindsMarch 31, 2025
• Highlights in Chronic Lymphocytic Leukemia From the 66th ASH Annual Meeting and ExpositionFebruary 20, 2025
• Flow Cytometry Evaluation of Acute Myeloid Leukemia Minimal Residual Disease Based on an Understanding of the Normal Maturation Patterns in the Blast CompartmentsFebruary 20, 2025
• Top 10 Ways Apps Are Helping OncologistsFebruary 20, 2025